In 2024, Sharma et al. explored the dual inhibition of CYP17A1 and histone deacetylase-6 (HDAC6) as a promising, novel strategy to identify molecules with therapeutic potential for the treatment of glioblastoma (Figure 13B) .166. This evidence concerns the gene HDAC6 and glioblastoma.